Medline Inc. is under investigation for potential securities fraud after the FDA issued a warning about significant manufacturing violations. The company's stock fell 7% in June and 13% in August following disclosures of quality issues and earnings losses related to remediation efforts. Investors who suffered losses may have legal options and are encouraged to contact Bleichmar Fonti & Auld LLP for representation.
Medline Inc. trades at USD 34.09 on Pluang as of Nov 04, 2026 18:11 WIB, holding steady with a 0.00% change in the last day. Despite the ongoing securities fraud investigation and past stock declines, investor interest remains strong with 98% of order activity on Pluang being buys. The stock's market cap stands at $29.91 billion, reflecting its significant presence in the health sector.
